Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 18,880 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 18,880 shares of Twist Bioscience stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $95.00, for a total value of $1,793,600.00. Following the sale, the chief executive officer directly owned 824,039 shares of the company’s stock, valued at $78,283,705. This represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Price Performance

TWST traded up $3.19 on Friday, reaching $99.84. The company had a trading volume of 4,274,502 shares, compared to its average volume of 1,512,186. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $104.23. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. The company has a market cap of $6.22 billion, a price-to-earnings ratio of -75.07 and a beta of 2.23. The business has a 50 day simple moving average of $66.16 and a 200 day simple moving average of $51.10.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm’s revenue was up 19.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.66) EPS. As a group, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Analyst Upgrades and Downgrades

TWST has been the subject of several recent research reports. Barclays boosted their price target on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday. Piper Sandler began coverage on shares of Twist Bioscience in a report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 target price on the stock. Robert W. Baird raised their target price on Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Canaccord Genuity Group assumed coverage on Twist Bioscience in a research report on Monday, June 15th. They set a “buy” rating and a $90.00 price target for the company. Finally, TD Cowen lifted their price objective on Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $74.60.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its position in Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after purchasing an additional 4,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after buying an additional 3,181 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after purchasing an additional 37,577 shares during the period. Intech Investment Management LLC grew its position in Twist Bioscience by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after purchasing an additional 4,591 shares during the period. Finally, Norges Bank bought a new stake in Twist Bioscience in the 2nd quarter worth approximately $737,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.